ABBV-1758 vs SHR-1707

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Alzheimer's Disease

Shared mechanism: Amyloid-beta (monoclonal antibody) · full Alzheimer's Disease pipeline

ABBV-1758

Developed by AbbVie

Phase 1/2 in Alzheimer's Diseasemonoclonal antibody (transferrin-receptor shuttle)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: October 2030 · NCT07599670 (registry estimate)

No aligned efficacy figure on record for this race.

SHR-1707

Developed by Jiangsu Hengrui Pharmaceuticals

Phase 2 in Alzheimer's Diseasemonoclonal antibody
Partial signal

NCT05681819 · Phase 1 · completed

The trial randomized 33 participants to SHR-1707 or placebo with triple-blinding, a design able to isolate a genuine drug effect, but its primary outcomes were safety measures rather than a cognitive or functional efficacy endpoint, and results have not yet been posted, so no effect on Alzheimer's disease could be established from this record.

No aligned efficacy figure on record for this race.

Results for Alzheimer's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointABBV-1758SHR-1707
CDR-SB, change—Not reported—Not reported
ADAS-Cog11, change—Not reported—Not reported
ADCS-ADL, change—Not reported—Not reported
MMSE, change—Not reported—Not reported
Amyloid PET, change (centiloids)—Not reported—Not reported

CDR-SB, change

ABBV-1758
—Not reported
SHR-1707
—Not reported

ADAS-Cog11, change

ABBV-1758
—Not reported
SHR-1707
—Not reported

ADCS-ADL, change

ABBV-1758
—Not reported
SHR-1707
—Not reported

MMSE, change

ABBV-1758
—Not reported
SHR-1707
—Not reported

Amyloid PET, change (centiloids)

ABBV-1758
—Not reported
SHR-1707
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ABBV-1758: no structured comparison results are available for Alzheimer's Disease.

SHR-1707: no structured comparison results are available for Alzheimer's Disease.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ABBV-1758's landscape · SHR-1707's landscape